Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | LPL | P06858 | 4/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formamide SCHEMBL28947237 | 0.90 | P2RX7 (0.47) | P2RX7MAPK1 | |
| SCHEMBL253582 | 0.85 | P2RX7 (0.56) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL4857793 | 0.81 | P2RX7 (0.58) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL662074 | 0.81 | P2RX7 (0.53) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL20010552 | 0.81 | P2RX7 (0.53) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL12381903 | 0.81 | P2RX7 (0.58) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL15181812 | 0.81 | P2RX7 (0.53) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL15181878 | 0.81 | P2RX7 (0.53) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL23873562 | 0.80 | P2RX7 (0.51) | P2RX7MAPK1 | |
| SCHEMBL4859383 | 0.80 | P2RX7 (0.56) | P2RX7MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 306 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132129-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES FOR TREATING CANCER | GENESIS THERAPEUTICS INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4720061-A1 | TREM2 AGONISTS | F. Hoffmann-La Roche AG (CH) | 2026-04-08 | — | — | EP | disclosed |
| US-20260078103-A1 | ISOQUINOLONES AS PI3K INHIBITORS | ONKURE, INC. (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4709719-A1 | 5-CYANO-1H-IMIDAZOLE-2-CARBOXAMIDE COMPOUNDS AS CSF1R INHIBITORS | Modulo Bio, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12565494-B2 | Inhibitors of human respiratory syncytial virus and metapneumovirus | MERCK SHARP & DOHME LLC | 2026-03-03 | — | — | US | disclosed |
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2025-12-25 | — | — | US | disclosed |
| EP-4663630-A1 | NOVEL BENZIMIDAZOLONE DERIVATIVE COMPOUND AS AUTOTAXIN INHIBITOR | LG Chem, Ltd. (KR) | 2025-12-17 | — | — | EP | disclosed |
| US-20250376452-A1 | 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors and Methods of Use Thereof | ENANTA PHARM INC (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250263390-A1 | NOVEL SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2025-08-21 | — | — | US | disclosed |
| EP-4602043-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES FOR TREATING CANCER | Genesis Therapeutics, Inc. (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20070167507-A1 | 4-Carbox pyrazole derivatives useful as anti-viral agents | GLAXO GROUP LIMITED (GB) | 2007-07-19 | — | — | US | disclosed |
| US-20070112002-A1 | 1,2-di(cyclic)substituted benzene compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-17 | — | — | US | disclosed |
| US-20070112002-A1 | 1,2-di(cyclic)substituted benzene compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-17 | — | — | US | disclosed |
| US-20070112002-A1 | 1,2-di(cyclic)substituted benzene compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-17 | — | — | US | disclosed |
| EP-1730116-A1 | 4-CARBOX PYRAZOLE DERIVATES USEFUL AS ANTI-VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-13 | — | — | EP | disclosed |
| US-20060276465-A1 | 1,2-di(cyclic) substituted benzene compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-12-07 | — | — | US | disclosed |
| US-20060258666-A1 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-16 | — | — | US | disclosed |
| EP-1698620-A1 | BENZENE COMPOUNDS DISUBSTITUTED WITH CYCLIC GROUPS AT THE 1- AND 2-POSITIONS | Eisai Co., Ltd. (JP) | 2006-09-06 | — | — | EP | disclosed |
| US-20050261291-A1 | 1,2-Di(cyclic)substituted benzene compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
| WO-2005092863-A1 | 4-CARBOX PYRAZOLE DERIVATES USEFUL AS ANTI-VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263390-A1 | NOVEL SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | GPER1, ESR2, ESRRA | P2RX7 1393/4885MAPK1 2883/4885LPL 3159/4885 |
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | ESRRA, ESRRB, ESR2 | P2RX7 2855/4885MAPK1 3886/4885LPL 799/4885 |
| US-20250376452-A1 | 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors and Methods of Use Thereof | HSD17B1, HSD17B13, HSD17B3 | P2RX7 4720/4885MAPK1 2464/4885LPL 382/4885 |
| US-20070112002-A1 | 1,2-di(cyclic)substituted benzene compounds | CCR10, HRH3, HRH1 | P2RX7 2146/4885MAPK1 668/4885LPL 4789/4885 |
| US-20260132129-A1 | 4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES FOR TREATING CANCER | PIK3R4, PIK3R1, PIK3R5 | P2RX7 929/4885MAPK1 514/4885LPL 2110/4885 |
| US-20060258666-A1 | c-fms kinase inhibitors | FLT3, FES, FER | P2RX7 2933/4885MAPK1 474/4885LPL 4342/4885 |
| US-12565494-B2 | Inhibitors of human respiratory syncytial virus and metapneumovirus | NHERF1, ZC3HAV1, SARS1 | P2RX7 4113/4885MAPK1 734/4885LPL 2766/4885 |
| US-20260078103-A1 | ISOQUINOLONES AS PI3K INHIBITORS | PIK3R5, PIK3R4, PIK3CA | P2RX7 1850/4885MAPK1 83/4885LPL 533/4885 |
| US-20070167507-A1 | 4-Carbox pyrazole derivatives useful as anti-viral agents | HAVCR2, RPL35, ZC3HAV1L | P2RX7 1620/4885MAPK1 3485/4885LPL 1506/4885 |
| US-20050261291-A1 | 1,2-Di(cyclic)substituted benzene compounds | CCR10, HRH3, HRH2 | P2RX7 1428/4885MAPK1 690/4885LPL 4807/4885 |
| US-20060276465-A1 | 1,2-di(cyclic) substituted benzene compounds | HRH3, CCR10, HRH1 | P2RX7 2354/4885MAPK1 836/4885LPL 4841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.